Proton pump inhibitors: Potential cost reductions by applying prescribing guidelines

BMC Health Services Research

Volumn 12, Issue 1, 2012, Pages

  Cahir, Caitriona ^a   Fahey, Tom ^a   Tilson, Lesley ^b   Teljeur, Conor ^c   Bennett, Kathleen ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c HEALTH INFORMATION AND QUALITY AUTHORITY   (Ireland)

Author keywords

Cost effective; Generic; Guidelines; Proton pump inhibitors

Indexed keywords

PROTON PUMP INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; COST CONTROL; DRUG COST; DRUG SUBSTITUTION; ECONOMICS; FACTUAL DATABASE; FEMALE; HUMAN; IRELAND; MALE; METHODOLOGY; MIDDLE AGED; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; STANDARD; STATISTICS;

ADOLESCENT; ADULT; AGED; COST SAVINGS; DATABASES, FACTUAL; DRUG COSTS; DRUG SUBSTITUTION; FEMALE; HUMANS; IRELAND; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84869133920     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-12-408     Document Type: Article

References (46)

1. Overprescribing proton pump inhibitors. Forgacs I, Loganayagam A, BMJ 2008 336 7634 2 3 10.1136/bmj.39406.449456.BE 18174564
2. IMS Health Report, IMS National Prescription Audit New Jersey: IMS 2010
3. Health Services Executive (HSE), Primary care reimbursement services: statistical analysis of claims and payments Dublin, Ireland: Health Services Executive (HSE) 2009
4. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. van Pinxteren B, Sigterman K, Bonis P, Lau J, Numans M, Cochrane Database of Systematic Reviews 2010 10 11 D002095
5. GORD in adults. Moayyedi P, Delaney B, BMJ Clinical Evidence 2008 6 403 1 20
6. IMS Health Report, Top 15 US pharmacuetical products by sales New Jersey: IMS 2009 http://www.imshealth.com/portal/site/ims/portal/front/articleC/0,2777, 6025-80528184-80530441,00.html
7. National Health Service (NHS), Drugs for dyspepsia. PACT centre pages London: NHS 2006 http://www.ppa.nhs.uk//news/pact-082004.htm
8. NHS National Institute for Excellence (NICE), Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. Technology appraisal guidance London: NICE 2000 http://www.nice.org.uk/nicemedia/pdf/proton.pdf
9. NHS National Institute for Excellence (NICE), Management of dyspepsia in adults in primary care London: NICE 2004 http://guidance.nice.org.uk/CG17
10. Inappropriate prescribing of proton pump inhibitors in primary care. Batuwitage BT, Kingham JG, Morgan NE, Bartlett RL, Postgraduate Medical Journal 2007 83 975 66 68 10.1136/pgmj.2006.051151 17267683
11. Overuse of acid-suppressive therapy in hospitalized patients. Nardino RJ, Vender RJ, Herbert PN, Am J Gastroenterol 2000 95 11 3118 3122 11095327
12. Overuse of proton pump inhibitors. Naunton M, Peterson GM, Bleasel MD, J Clin Pharm Ther 2000 25 5 333 340 10.1046/j.1365-2710.2000.00312.x 11123484 (Pubitemid 32002877)
13. Continuation of Proton Pump Inhibitors from Hospital to Community. Grant K, Al-Adhami N, Tordoff J, Livesey J, Barbezat G, Reith D, Pharmacy World & Science 2006 28 4 189 193 10.1007/s11096-006-9028-4 23256125 (Pubitemid 44673747)
14. Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey. Parente F, Cucino C, Gallus S, Bargiggia S, Greco S, Pastore L, et al. Aliment Pharmacol Ther 2003 17 12 1503 1506 10.1046/j.1365-2036.2003.01600.x 12823152 (Pubitemid 36833294)
15. An evaluation of the use of proton pump inhibitors. Walker NM, McDonald J, Pharmacy World & Science 2001 23 3 116 117 10.1023/A:1011278030001 23256125 (Pubitemid 32607023)
16. Proton pump inhibitors: a survey of prescribing in an Irish general hospital. Mat Saad AZ, Collins N, Lobo MM, O'Connor HJ, Int J Clin Pract 2005 59 1 31 34 15707461 (Pubitemid 40260110)
17. Use of Gastric Acid-Suppressive Agents and the Risk of Community-Acquired Clostridium difficile-Associated Disease. Dial S, Delaney JAC, Barkun AN, Suissa S, JAMA: The Journal of the American Medical Association 2005 294 23 2989 2995 10.1001/jama.294.23.2989 (Pubitemid 41817660)
18. Use of Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia: A Population-Based Case-control Study. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J, Arch Intern Med 2007 167 9 950 955 10.1001/archinte.167.9.950 17502537 (Pubitemid 46762758)
19. Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia. Sarkar M, Hennessy S, Yang Y-X, Ann Intern Med 2008 149 6 391 398 18794558
20. Acid-Suppressive Medication Use and the Risk for Hospital-Acquired Pneumonia. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER, JAMA: The Journal of the American Medical Association 2009 301 20 2120 2128 10.1001/jama.2009.722
21. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the women's health initiative. Gray SL, LaCroix AZ, Larson J, Robbins J, Cauley JA, Manson JE, et al. Arch Intern Med 2010 170 9 765 771 20458083
22. Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn. Goeree R, O'Brien BJ, Blackhouse G, Marshall J, Briggs A, Lad R, Value in Health 2002 5 4 312 328 10.1046/j.1524-4733.2002.54145.x 12102694 (Pubitemid 36998744)
23. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. Brown T, Hooper L, Elliott R, Payne K, Webb R, Roberts C, et al. Health Technology Assessment 2006 10 38 1 420 17134596
24. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Expert Review of Pharmacoeconomics & Outcomes Research 2010 10 6 707 722 10.1586/erp.10.72 22997674
25. Policies to enhance prescribing efficiency in Europe: findings and future implications. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, et al. Front Pharmacol 2011 1 141 1 16
26. WHO Collaborating Centre for Drug Statistics Methodology, Anatomical Therapeutic Chemical (ATC) Classification Index Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology 2010
27. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Andersson K, Sonesson C, Petzold M, Carlsten A, Lönnroth K, Pharmacoepidemiology and Drug Safety 2005 14 5 341 348 10.1002/pds.1055 15624198 (Pubitemid 40716327)
28. Lansoprazole overutilization: methods for step-down therapy. Pohland CJ, Scavnicky SA, Lasky SS, Good CB, The American Journal of Managed Care 2003 9 5 353 358 12744297 (Pubitemid 36612116)
29. Managing dyspepsia without alarm signs in primary care: new national guidance for England and Wales. Mason JM, Delaney B, Moayyedi P, Thomas M, Walt R, Aliment Pharmacol Ther 2005 21 9 1135 1143 10.1111/j.1365-2036.2005.02445.x 15854176 (Pubitemid 40646540)
30. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Godman B, Sakshaug S, Berg C, Wettermark B, Haycox A, Expert Review of Pharmacoeconomics & Outcomes Research 2011 11 1 121 129 10.1586/erp.10.87 22997674
31. Step down management of gastroesophageal reflux disease. Inadomi JM, Jamal R, Murata G, Hoffman R, Lavezo L, Vigil J, et al. Gastroenterology 2001 121 5 1095 1100 10.1053/gast.2001.28649 11677201 (Pubitemid 33022089)
32. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Krol N, Wensing M, Haaijer-Ruskamp F, Muris JWM, Numans ME, Schattenberg G, et al. Aliment Pharmacol Ther 2004 19 8 917 922 10.1111/j.1365-2036.2004.01928.x 15080853 (Pubitemid 38534821)
33. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Bjornsson E, Abrahamsson H, Simren M, Mattsson N, Jensen C, Agerforz P, et al. Aliment Pharmacol Ther 2006 24 6 945 954 10.1111/j.1365-2036.2006.03084.x 16948806 (Pubitemid 44326375)
34. Barry M, Economies of drug usage in the Irish healthcare setting: Department of Health Dublin, Ireland 2009
35. Current and future trends in the use of generic medicines in the UK. Darroch C, Kay A, Pharm J 2008 281 507 509
36. On-Demand and Intermittent Therapy for Gastro-Oesophageal Reflux Disease: Economic Considerations. Inadomi JM, PharmacoEconomics 2002 20 9 565 576 10.2165/00019053-200220090-00001 12141885
37. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G, Am J Gastroenterol 2000 95 2 395 407 10.1111/j.1572-0241.2000.01759.x 10685741 (Pubitemid 30106167)
38. Reducing community dyspepsia drug costs: a controlled trial. Valori RM, Brown CM, Strangeways P, Bradburn M, Gut 2001 49 4 495 501 10.1136/gut.49.4.495 11559645 (Pubitemid 32896978)
39. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. McGinn D, Godman B, Lonsdale J, Way R, Wettermark B, Haycox A, Expert Review of Pharmacoeconomics & Outcomes Research. 2010 10 1 73 85 10.1586/erp.09.73 22997674
40. Effect of implementation of a dyspepsia and Helicobacter pylori eradication guideline in primary care. Cardin F, Zorzi M, Bovo E, Guerra C, Bandini F, Polito D, et al. Digestion 2005 72 1 1 7 10.1159/000087215 16088146 (Pubitemid 41254148)
41. Ongoing Pharmaceutical Reforms in France: Implications for Key Stakeholder Groups. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier J-P, Applied Health Economics and Health Policy 2010 8 1 7 24 20038190
42. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL, Expert Review of Pharmacoeconomics & Outcomes Research 2009 9 1 65 83 10.1586/14737167.9.1.65 22997674
43. Pharmaceutical pricing and reimbursement in Europe. Kanavos P, Scrip reports regulatory affairs report series London: Scrip reports 2005
44. Department of Health and Children, Proposed model for reference pricing and generic substitution Dublin, Ireland: Department of Health and Children 2010
45. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Garuoliene K, Godman B, Gulbinovic J, Wettermark B, Haycox A, Expert Review of Pharmacoeconomics & Outcomes Research. 2011 11 3 343 349 10.1586/erp.11.24 22997674
46. Health Services Executive (HSE), Agreement between the Irish Pharmaceutical Healthcare Association LTD and the Health Services Executive on the supply terms, conditions and prices of medicines supplied to the health services Dublin, Ireland: Health Services Executive (HSE) 2010